Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Repros Therapeutics
Repros Therapeutics Announces Settlement with Major Creditors
November 13th, 2009
Repros Therapeutics (NasdaqGM:RPRX) announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program. Previously the Company announced in early August 2009 that it had voluntarily suspended dosing of all patients in its Proellex clinical trials. The FDA subsequently notified Repros that the Proellex program was placed on full clinical hold due to the observation of increased liver enzymes in a number of patients treated with Proellex. These elevated liver enzyme observations occurred during the time that the Company was attempting...
Source: Food & Drug Law Weekly (2009-11-13)
|
